CY1118576T1 - Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23 - Google Patents

Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23

Info

Publication number
CY1118576T1
CY1118576T1 CY20171100096T CY171100096T CY1118576T1 CY 1118576 T1 CY1118576 T1 CY 1118576T1 CY 20171100096 T CY20171100096 T CY 20171100096T CY 171100096 T CY171100096 T CY 171100096T CY 1118576 T1 CY1118576 T1 CY 1118576T1
Authority
CY
Cyprus
Prior art keywords
antigen
human
proteins bound
protein
binding proteins
Prior art date
Application number
CY20171100096T
Other languages
English (en)
Inventor
Jennifer E Towne
Janet D Cheng
Jason C O’Neill
Yu Zhang
Yu Sun
Heather Cerne
Derek E Piper
Randal R Ketchem
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43413789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118576(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1118576T1 publication Critical patent/CY1118576T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται πρωτεΐνες δεσμευόμενες με αντιγόνο οι οποίες δεσμεύονται με ανθρώπινη πρωτεΐνη IL-23. Παρέχονται επίσης νουκλεϊκά οξέα που κωδικοποιούν την δεσμευόμενη με αντιγόνο πρωτεΐνη, φορείς, και κύτταρα που την κωδικοποιούν όπως επίσης και χρήση των πρωτεϊνών που δεσμεύονται με αντιγόνο IL-23 για διαγνωστικούς και θεραπευτικούς σκοπούς.
CY20171100096T 2009-10-26 2017-01-24 Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23 CY1118576T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25498209P 2009-10-26 2009-10-26
US38128710P 2010-09-09 2010-09-09
PCT/US2010/054148 WO2011056600A1 (en) 2009-10-26 2010-10-26 Human il-23 antigen binding proteins

Publications (1)

Publication Number Publication Date
CY1118576T1 true CY1118576T1 (el) 2017-07-12

Family

ID=43413789

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100096T CY1118576T1 (el) 2009-10-26 2017-01-24 Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23

Country Status (37)

Country Link
US (9) US8722033B2 (el)
EP (3) EP3181586A1 (el)
JP (5) JP5930968B2 (el)
KR (3) KR101568461B1 (el)
CN (3) CN104761642A (el)
AR (1) AR078778A1 (el)
AU (1) AU2010315557B2 (el)
BR (2) BR112012009854B8 (el)
CA (2) CA2778112C (el)
CL (1) CL2012001096A1 (el)
CO (1) CO6531481A2 (el)
CR (1) CR20120210A (el)
CY (1) CY1118576T1 (el)
EA (1) EA025366B1 (el)
ES (1) ES2613236T3 (el)
HK (2) HK1177469A1 (el)
HR (1) HRP20170037T1 (el)
HU (1) HUE030871T2 (el)
IL (3) IL219241A (el)
JO (1) JO3244B1 (el)
LT (1) LT2493925T (el)
MA (1) MA33757B1 (el)
MX (1) MX358249B (el)
MY (1) MY156286A (el)
NZ (2) NZ599875A (el)
PE (2) PE20121579A1 (el)
PL (1) PL2493925T3 (el)
PT (1) PT2493925T (el)
RS (1) RS55666B1 (el)
SG (2) SG10202103260TA (el)
SI (1) SI2493925T1 (el)
TN (1) TN2012000167A1 (el)
TW (2) TWI432210B (el)
UA (1) UA113609C2 (el)
UY (1) UY32971A (el)
WO (1) WO2011056600A1 (el)
ZA (1) ZA201203058B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP6126532B2 (ja) 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
US9012161B2 (en) * 2011-01-25 2015-04-21 Monell Chemical Senses Center Methods of identifying molecules that provide or enhance sweet taste
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
MX368653B (es) * 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
NZ712294A (en) * 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
AU2014238148A1 (en) * 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
CA2945498A1 (en) * 2014-04-15 2015-10-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind wisp1
EP4198059A1 (en) 2014-05-27 2023-06-21 The University of Queensland Modulation of cellular stress
WO2016010927A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
BR112018005175A2 (pt) 2015-09-17 2018-10-16 Amgen Inc predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
ES2857552T3 (es) * 2015-10-19 2021-09-29 Takeda Pharmaceuticals Co Inmunoensayo para detectar cininógenos de alto peso molecular escindido
MX2018007589A (es) 2015-12-22 2018-11-09 Amgen Inc Ccl20 como indicador de respuesta clinica a antagonistas de il23.
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
EP4074734A1 (en) * 2017-08-04 2022-10-19 The Hospital for Sick Children Nanoparticle platform for antibody and vaccine delivery
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
US20210277105A1 (en) * 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
KR20220016954A (ko) * 2019-06-04 2022-02-10 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
AU2020308463A1 (en) * 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
CN112807428A (zh) * 2020-06-12 2021-05-18 江苏荃信生物医药有限公司 包含抗人白介素23单克隆抗体的药物组合物
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
EP4359444A1 (en) * 2021-06-25 2024-05-01 Sangamo Therapeutics, Inc. Antigen binders specific for il-23r and uses thereof
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993010227A1 (en) 1991-11-14 1993-05-27 Charles Weissmann Transgenic animals lacking prion proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
WO1999054357A1 (fr) 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Nouvelle proteine du type cytokine
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
ES2300276T5 (es) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
DK1576011T3 (da) 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
AU2004219625B9 (en) 2003-03-10 2010-12-23 Merck Sharp & Dohme Corp. Uses of IL-23 agonists and antagonists; related reagents
AU2004239288B2 (en) 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
TW201444869A (zh) 2005-06-30 2014-12-01 Abbvie Inc Ｉｌ-１２／ｐ４０結合蛋白
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
CN1955248B (zh) 2005-10-28 2011-10-12 安集微电子（上海）有限公司 钽阻挡层用化学机械抛光浆料
JP2009521933A (ja) 2005-12-28 2009-06-11 セントカー・インコーポレーテツド 乾癬および関連障害を評価および処置するためのマーカーおよび方法
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
JP5931442B2 (ja) 2008-08-27 2016-06-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120027799A1 (en) 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
RU2012114854A (ru) 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
KR20130010461A (ko) 2010-02-18 2013-01-28 브리스톨-마이어스 스큅 컴퍼니 Ｉｌ―２３에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
CA2805653A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
BR112013008528A2 (pt) 2010-10-06 2019-09-24 Abbvie Inc métodos para tratar psoríase
US9717791B2 (en) 2010-10-08 2017-08-01 Novartis Ag Methods of treating psoriasis using IL-17 antibody
JP6126532B2 (ja) 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
TW201242976A (en) 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
NZ712294A (en) 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
BR112018005175A2 (pt) 2015-09-17 2018-10-16 Amgen Inc predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
MX2018007589A (es) 2015-12-22 2018-11-09 Amgen Inc Ccl20 como indicador de respuesta clinica a antagonistas de il23.
US20210277105A1 (en) 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
EP4017880A4 (en) 2019-08-21 2023-10-11 Astrazeneca Collaboration Ventures, LLC USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE

Also Published As

Publication number Publication date
AR078778A1 (es) 2011-11-30
BR112012009854A8 (pt) 2019-10-08
LT2493925T (lt) 2017-04-25
EP2493925A1 (en) 2012-09-05
BR122020002402B1 (pt) 2022-02-08
ES2613236T3 (es) 2017-05-23
KR20120090091A (ko) 2012-08-16
KR20140062186A (ko) 2014-05-22
EP3656790A1 (en) 2020-05-27
ZA201203058B (en) 2013-01-30
CA3030092C (en) 2023-12-19
BR112012009854B8 (pt) 2021-05-25
EA025366B1 (ru) 2016-12-30
HRP20170037T1 (hr) 2017-03-10
US9487580B2 (en) 2016-11-08
SI2493925T1 (sl) 2017-05-31
JP2013507991A (ja) 2013-03-07
CR20120210A (es) 2012-07-20
EP3181586A1 (en) 2017-06-21
WO2011056600A1 (en) 2011-05-12
TWI432210B (zh) 2014-04-01
KR101568461B1 (ko) 2015-11-12
MA33757B1 (fr) 2012-11-01
US20170002070A1 (en) 2017-01-05
JP2016102122A (ja) 2016-06-02
HK1212357A1 (en) 2016-06-10
CO6531481A2 (es) 2012-09-28
CA3030092A1 (en) 2011-05-12
BR112012009854B1 (pt) 2020-12-15
BR122020002402B8 (pt) 2022-03-29
PL2493925T3 (pl) 2017-09-29
AU2010315557B2 (en) 2014-02-27
BR112012009854A2 (pt) 2016-11-22
CN104761642A (zh) 2015-07-08
US20210024626A1 (en) 2021-01-28
JP2022033730A (ja) 2022-03-02
US9951129B2 (en) 2018-04-24
TN2012000167A1 (en) 2013-12-12
PT2493925T (pt) 2017-02-14
MX358249B (es) 2018-08-10
TW201121567A (en) 2011-07-01
AU2010315557A1 (en) 2012-09-20
RS55666B1 (sr) 2017-06-30
IL274871A (en) 2020-07-30
UA113609C2 (xx) 2017-02-27
MY156286A (en) 2016-01-29
CA2778112C (en) 2019-02-26
PE20121579A1 (es) 2012-12-13
NZ625630A (en) 2016-09-30
US12012449B2 (en) 2024-06-18
US20140212428A1 (en) 2014-07-31
JO3244B1 (ar) 2018-03-08
CA2778112A1 (en) 2011-05-12
EA201270571A1 (ru) 2012-09-28
KR20160118278A (ko) 2016-10-11
US20190322737A1 (en) 2019-10-24
US20220056122A1 (en) 2022-02-24
NZ599875A (en) 2014-10-31
JP2020018308A (ja) 2020-02-06
CN102741285A (zh) 2012-10-17
JP5930968B2 (ja) 2016-06-08
IL244801B (en) 2020-05-31
HK1177469A1 (en) 2013-08-23
SG10201800682SA (en) 2018-03-28
CL2012001096A1 (es) 2012-09-28
JP7023908B2 (ja) 2022-02-22
US20130004501A1 (en) 2013-01-03
US20200181255A1 (en) 2020-06-11
US20190071498A1 (en) 2019-03-07
IL219241A (en) 2016-03-31
CN110407936A (zh) 2019-11-05
US20210230267A1 (en) 2021-07-29
KR101652609B1 (ko) 2016-08-30
HUE030871T2 (en) 2017-06-28
IL244801A0 (en) 2016-04-21
CN102741285B (zh) 2015-03-25
JP2018117626A (ja) 2018-08-02
PE20161327A1 (es) 2016-12-03
UY32971A (es) 2010-11-30
SG10202103260TA (en) 2021-05-28
IL219241A0 (en) 2012-06-28
JP7278355B2 (ja) 2023-05-19
MX2012004868A (es) 2012-08-03
TW201417830A (zh) 2014-05-16
EP2493925B1 (en) 2016-11-23
US8722033B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1122658T1 (el) Αντισωματα συνδεσης ανθρωπινου cgrp υποδοχεα
CY1119755T1 (el) Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms
CY1123739T1 (el) Αντισωματα anti-cd38
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1119892T1 (el) Φορεις και αλληλουχιες για την αγωγη ασθενειων
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
ECSP12012272A (es) Proteínas que se unen al tnf-?
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1118014T1 (el) Aνti-il-23 αντισωματα
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
UA109633C2 (uk) Антитіло людини проти тканинного фактора
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1
CY1114496T1 (el) Διασταυρωμενων-ειδων-ειδικο πεδιο συνδεσης cd3-εψιλον
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a